Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
暂无分享，去创建一个
D. Schadendorf | K. Flaherty | P. Ascierto | R. Dummer | A. Arance | I. Krajsová | C. Garbe | M. Mandalà | H. Gogas | R. Gutzmer | C. Robert | A. Gollerkeri | C. Loquai | G. Liszkay | C. Dutriaux | M. Pickard | J. D. Groot